melanoma
Lifileucel received FDA approval for unresectable/metastatic melanoma after PD-1/PD-L1 failure. The C-144-01 study showed median duration of response 36.5 months, median OS 13.9 months, 5-year OS rate 19.7%. However, current TIL therapy requires intensive lymphodepletion and high-dose IL-2,…
melanoma
Bile acids (BAs) are significantly enriched in melanoma and breast cancer tumor microenvironments. BA enrichment drives tumor aerobic glycolysis and immune evasion by activating and stabilizing the FXR-RARα complex, upregulating glycolytic pathways and impairing anti-tumor immunity. BA depletion…
melanoma
Combining scRNA-seq and transcriptomics with PSO-SVM machine learning (particle swarm optimization + support vector machine), researchers identified 5 key SKCM metastasis-related genes: SFN, S100A8, KLF5, ARL4D, and TINCR. Expression differences were confirmed at single-cell level across different…
melanoma
A 70-year-old male with sinonasal mucosal melanoma progressed on nivolumab-ipilimumab (unresectable). After switching to nivolumab-relatlimab plus site-directed radiation, he achieved complete response after 8 cycles. Treatment interruption for suspected immune toxicity led to eventual progression.…
lung-cancer
17 metastatic lung cancer and melanoma treatment responders who received CALM therapy described their experience. Four themes emerged: twilight zone between illness/health, ongoing uncertainty, struggling to adapt, and shift over time. CALM was valued for safe processing space, addressing…
melanoma
Oncolytic viruses — engineered viruses that preferentially infect and kill cancer cells — are a promising cancer immunotherapy approach. When injected directly into a tumor, they can sometimes trigger shrinkage of distant, uninjected tumors as well. But exactly how this 'abscopal' effect works at…
colorectal-cancer
mRNA-delivered fusion protein combines immune activation and direct cell killing for a new approach to cancer gene therapy mRNA-based cancer therapeutics are an emerging area, building on the success of mRNA vaccines. This study engineered a novel fusion protein combining interferon-gamma (IFN-γ) — which activates immune responses — with the intracellular domain
melanoma
Three clinical features identify thin melanomas at high risk of recurring within two years: age over 65, ulceration, and mitotic rate Thin melanomas — classified as T1, meaning the tumor is ≤1mm deep — are generally considered low-risk and treated with surgery alone. Yet thin melanomas account for more than 25% of